Organic compounds -- part of the class 532-570 series inventions 04/09

20090111989 - Organic light emitting materials with anionic ligand: Emissive phosphorescent organometallic compounds that produce electroluminescence and organic light emitting devices employing such emissive phosphorescent organometallic compounds are provided. More specifically the present invention is directed to novel primarily non-emitting ligands which produce a blue shift in emitted light when associated with a cyclometallated ligand.... Agent: Kenyon & Kenyon LLP

20090111990 - Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes: wherein R1 is a C2-C20 aliphatic, a C3-C20 cycloaliphatic, or a C3-C20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent; R2 is a C1-C10 aliphatic radical, or a C3-C10 cycloaliphatic radical; R3 is hydrogen or a C1-C10 aliphatic... Agent: General Electric Company Global Research

20090111991 - Coupling process for preparing quinolone intermediates: Process for making 7-cycloamino-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids. Borate ester compounds suitable for use in such process.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090111992 - Alkyl ether derivatives or salts thereof: wherein each of R1 and R2 represents one or more groups selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090111993 - Process for preparing beta-(fluorophenyl)-propanoate ester derivatives: A process for preparing a compound of formula (I) comprising reacting a compound of formula (II) with a fluorinated boron species of formula (III) in the presence of: an alcohol; a rhodium (I) pre-catalyst species; a suitable ligand that binds to the rhodium (I) pre-catalyst species to form a catalyst... Agent: Fish & Richardson P.C.

20090105479 - 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-napthyridene-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same: The invention is directed to a compound of the structural formula (22) (22) crystal form of structural formulae (21) and its free acid, pharmaceutical compositions comprising these compounds and methods of preparing and using these compounds.... Agent: Merck And Co., Inc

20090105480 - Process for the preparation of a dpp-iv inhibitor: wherein R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and the pharmaceutically acceptable salts thereof. The invention also relates to two crystalline forms... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090099361 - Novel tantalum and niobium compounds: The present invention relates to specific, novel tantalum and niobium compounds which can serve as starting materials for the preparation of chemical vapour deposition (CVD) precursors.... Agent: Connolly Bove Lodge & Hutz, LLP

20090099362 - Process for the preparation of gabapentin hydrochloride: A process for preparation of gabapentin hydrochloride by converting 1,5-dicyano-2,4-dioxo-3-azaspiro[5,5]-undecane into 1,5-diaminoformyl-2,4-dioxo-3-azaspiro[5,5]-undecane at a temperature of 65° C. to 85° C. in the presence of a strong acid, and then carrying out Hofmann rearrangement under an alkaline condition. The starting material of the process is readily available. The process is... Agent: Connolly Bove Lodge & Hutz, LLP

20090099363 - Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate: The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090099364 - Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine: This invention relates to an improved process for the preparation of (2S,3S)-2-benzhydryl-N-(5-tent-butyl-2-methoxybenzyl)quinuclidin-3-amine, (hereinafter “compound of Formula I”) and its pharmaceutically acceptable salts. In particular, the invention is directed to an improved synthesis of the monohydrate citrate salt of the compound of Formula (Ia).... Agent: Pfizer Inc.

20090099365 - Processes for solifenacin preparation: Processes for preparing solifenacin comprising distilling ethanol and organic solvent from a reaction mixture and recycling the organic solvent are described. Also described are processes for reducing solifenacin diastereomeric and enantiomeric impurities.... Agent: Kenyon & Kenyon LLP

20090099366 - Process and intermediates for preparing integrase inhibitors: The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.... Agent: Viksnins Harris & Padys Pllp

20090099367 - Process for preparing a leukotriene antagonist: Process for preparing montelukast or a pharmaceutically acceptable salt thereof, especially its sodium salt, that comprises the condensation of an aldehyde and 7-chloro-2-methylquinoline. Moreover, novel intermediates useful for the synthesis of montelukast are described as well as their preparation.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090099368 - Dehydrogenation process: Processes comprising: providing a dehydrogenatable compound; and subjecting the dehydrogenatable compound to a dehydrogenation reaction at a temperature of from 150 to 400° C., in the presence of oxygen, and at a temperature profile of the dehydrogenation reaction which does not differ substantially from the temperature profile of the dehydrogenation... Agent: Connolly Bove Lodge & Hutz, LLP

20090093634 - Substituted pyrroline kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20090093635 - Process for making polymorph from i of (s) - (+) -methyl-alpha- (2-chlorophenyl) -6, 7-dyhidro-thieno- [3, 2-c] pyridine-5 (4h) -acetate hydrogen sulfate: The invention relates to a process for the preparation of the pharmaceutically applicable polymorph Form I of (S)-(+)-methyl-α-(2-chlorophenyl)-6,7-dyhidro-thieno[3,2-c]-pyridine-5(4H)-acetate hydrogen sulfate of formula I; by reacting (S)-(+)-methyl-α-(2-chlorophenyl)-6,7-dyhidro-thieno[3,2-c]pyridine-5(4H)-acetate and sulfuric acid in the presence of solvents which comprises dissolving (S)-(+)-methyl-α-(2-chlorophenyl)-6,7-dyhidro-thieno[3,2-c]pyridine-5(4H)-acetate in an ether; mixing this solution with a solution of a C6-C11... Agent: K.f. Ross P.C.

20090093636 - Process for making montelukast and intermediates therefor: e

20090093637 - Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles: This invention concerns the synthesis of highly substituted pyrazoles, which are structural components of pharmacological compounds, through reaction of hydrazones with nitroolefins.... Agent: Philip S. Johnson Johnson & Johnson

20090093638 - Allylic oxidations catalyzed by dirhodium catalysts under aqueous conditions: The present invention relates to compositions and methods for achieving the efficient allylic oxidation of organic molecules, especially olefins and steroids, under aqueous conditions. The invention concerns the use of dirhodium (II,II) “paddlewheel complexes, and in particular, dirhodium carboximate and tert-butyl hydroperoxide as catalysts for the reaction. The use of... Agent: Edell, Shapiro & Finnan, LLC